Speakers
Professor and Founding Chair, Immunology Director, Institute of Neuro- Immune Pharmacology Associate Dean, BioMedical Research, FIU.
Nair and his colleagues discovered the suppressor factor in cancer serum (1978) and first reported that intravenous drug users manifest low natural killer cell activity (1986) and morphine induces apoptosis of normal lymphocytes (1997). In 1988 Dr Nair in collaboration with Dr Ravi Pottathil reported for the first time (PNAS) that HIV recombinant purified gene product possess significant biological activities. His original reports that cocaine increases the sensitivity to HIV infection by increasing the HIV coreceptors and methamphetamine
 
exacerbates the HIV replication in dendritic cells had a profound effect on the role of these drugs on HIV disease progression. His recent research mainly involves the role of different drugs of abuses such as alcohol, morphine, cocaine and methamphetamine on neuro-AIDS and therapeutic approach to control Neuro-AIDS by specific drug targeting to brain using nanotechnology.
Nair is the first FIU researcher to earn a prestigious MERIT Award from the National Institutes of Health recognizing outstanding competence and productivity in research (2008-2018). Nair is also the recipient of University of Michigan Distinguished Research Scientist Award (1990),
 
Exceptional Research Scholar Award from State University of New York (2005), Excellence in Faculty Scholarship Award from FIU (2008) , Presidential Leadership Operational Excellence Award from FIU in 2009 and FIU's Top Research Scholar Award in 2010.
Nair has published more than 100 papers as first and/or senior author, mentored more than 50 undergraduate, graduate, postdoctoral fellows, high school and minority students, served in various committees, organized various national and international conferences, chaired number of scientific sessions and served in various NIH study sections committees as chair/ member since 1980.

Jag Khalsa, Ph.D.
National Institute of Health Bethesda, MD, USA Dr. Jag Khalsa is the Chief of the Medical Consequences Branch in the Division of Pharmacotherapies and Medical Consequences of Drug Abuse, the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), DHHS. He received his Ph.D. in neuro-psycho-pharmacology from the University of Mississippi and postdoctoral training in CNS/Cardiovascular pharmacology at SK&F (now Gla xoSmith Kline), and Toxicology at the Stanford Research Institute. The Branch is responsible for developing and administering a national and international program of clinical research on Medical and Health Consequences of Drug Abuse and co- occurring infections (HIV, HCV, TB, STD, and others) including metabolic,
 
endocrine and gastrointestinal disorders in drug addicts with or without HIV infection; pharmacokinetic / pharmacodynamic drug-drug interactions among drugs of abuse, and pharmacotherapeutic agents used in the treatment of infections (HIV, HCV) and drug addiction; and misuse of prescription drugs. Prior to joining NIDA in 1987, he served for about 10 years as a pharmacologist /toxicologist assessing safety including carcinogenic and teratogenic potential of chemicals [new drugs-INDs and NDAs] and food additives) and clinical evaluator (adverse consequences of drugs) at the US Food & Drug Administration. He has several publications in the fields of pharmacology, toxicology, epidemiology and medicine.
 
He has received several awards of meritorious/distinguished service from the FDA Commissioner, Director of Bureau of Foods, FDA, NIDA Director, NIH Director, Society on NeuroImmune Pharmacology, the Life Time Achievement Awards from the U.S. Sikh Council on Religion and Education, and the International Conference on Molecular Medicine,the American society of Addiction Medicine Preseidential Award for outstanding contributions to the field of addiction medicine, and a commendation from the US Congressman E. Cummings. Dr. Khalsa also has degrees in Chemistry (B.S), pharmacy (B.Pharm & M.Pharmacology/ pharmacognosy [herbal pharmacology]), all from Gujarat University, India.

Ravi Pottathil is a recognized authority in the field of In-vitro diagnostics. In this regard, from 1985 to 1992, he was the Section Manager for retroviruses, tumor markers and PCR diagnostics at Hoffman La Roche. Ravi has co-founded a number of companies including: Specialty Biosystems, Inc. a venture of Specialty Labs, one of the largest independent reference laboratories in California, AccuDx Inc. in California, OnQuest in California, Specialty Ranba xy, India and Specialty International in Singapore. He served as Vice President of XLTechGroup and 2003 -2008 and Chief Process Scientist at PetroAlgae [2008-2011]. He has also been on the advisory board of several private and public organizations, including the World
 
Health Organization and Global Biopharma, New York and Aethlon Medical of California, Green Ocean Innovation and Spectral Diagnostics. Currently he is CEO of AccuDx Corporation. In the academic world, Ravi has been Assistant Professor at the University of Maryland School of Medicine, Associate Professor at the City of Hope Medical Center in California, and Adjunct Professor in Virology at Rutgers University in New Jersey. As a virologist and molecular biologist, Ravi has over 50 refereed publications to his credit. AccuDx has been working on nano-materials for the past 15 years. At AccuDx Ravi developed proprietary methods for the large scale production of Uniform Nanoparticles, Nano-based security
 
tags, structurally integrated bar-codes and human in-vitro diagnostic products that incorporated nano-structures. Ravi has been teaching nanotechnology at various National and International forums. Currently he has several academic appointments including as Distinguished Professors at Marathwada Institute of Technology, Aurangabad, India and North Western A&F University, Yangling, China Ravi received his undergraduate training in Biological Sciences from the University of Kerala, India and completed his MSc and Ph.D in Applied Biology [Cancer Research] from Bombay University. He did his postdoctoral training in Genetics at The Jackson Laboratories Bar Harbor, Maine, and in Medical Virology at Duke University in the USA.

Sakhrat Khizroev is an Engineer and an Educator with a research focus on Nano Technology applications. In 2011, he rejoined FIU as a tenured Professor at the Department of Electrical and Computer Engineering and one of the two founding Co-Directors (together with Professor Madhavan Nair at the College of Medicine (COM)) of the new Center for NanoMedicine (CNM) based at the FIU College of Engineering and Computing (CEC) and the College of Medicine and the School of Arts and Sciences (SAS). The main mission of the Center is to use Nano Technology to bridge advances in fundamental research with the current need in medicine. The focus on practical research which could impact everyday clinical applications is the signature strategy of the Center. From 2006 to 2010, Khizroev was a tenured Professor at the Department of Electrical Engineering, University of California, Riverside (UCR), where his group conducted several groundbreaking demonstrations in the
 
area of nanoelectronics and nanodiagnostics. During his prior appointment at FIU, between 2003 and 2006, Dr. Khizroev contributed to the development of the Focused Ion Beam (FIB) laboratory within the Motorola Nano Technology Facility, making FIU the first university across the globe where the popular tool was used from an unconventional angle as a nanodevice prototyping machine. Threedimensional (3-D) magnetic memory and Nanolasers for 5-nm diagnostics are some of the pioneering and patented technologies which came from the Khizroev group at FIU and were later advanced at UCR.
Prior to his academic career, Khizroev spent almost four years as a Research Staff Member with Seagate Research (1999-2003) and one year as a predoctoral intern with IBM Almaden Research Center (1997-1998). He holds over 28 granted patents and 130 provisional patents with IBM, Seagate, CMU, FIU, and UCR. He has authored/co-authored over 100 refereed papers, 5 books and book
 
chapters in the broad area of nanotechnology devices. He presented over 100 talks including many invited seminars and colloquia at international conferences and meetings. He acted as a guest science and technology commentator on television and radio programs across the globe. He served as Associate Editor for IEEE Transactions on Nano Technology, a guest editor for Nano Technology and IEEE Transactions on Magnetics and serves on editorial boards of several Science and Technology journals. Together with his former graduate students, he co-founded several hightechnology start-ups funded through SBIR grants by the National Science Foundation. Dr. Khizroev received a BS in Quantum Electronics and Applied Physics from Moscow Institute of Physics and Technology, a MS in Physics from the University of Miami, and a PhD in Electrical and Computer Engineering from Carnegie Mellon University in 1992, 1994, and 1999, respectively.

Dr. Maguire is currently the Founder, CEO of BioRegenerative Sciences, Inc. San Diego, CA. He also serves as President of La Jolla Research Institute, a non-profit institute for medical neuroscience research and education, and President of San Diego Neuroscience Group, a nonprofit educational society for the teaching
 
and promotion of neuroscience, affiliated with Scripps Research Institute. His research interests include stem cells, systems biology-based therapeutics, regeneration, neuroscience, cancer, cellular therapy, metabolomics, neuroprotection, & neurodegenerative disorders. Dr. Maguire has had extensive experience in both the business and academic
 
arenas. He received his PhD from University of Houston College of Optometry, in Physiological Optics and conducted postdoctoral work at both University of Miami School of Medicine, Bascom Palmer Eye Institute and University of California, Berkeley, Neurobiology Group, Depts. of Electrical Engineering and Molecular and Cell Biology,

Simon serves as President, Chief Executive Officer and Managing Director of ACN Securities. In addition, he practices law for selected clients and is a principal in a consulting group that focuses on technology commercialization and Venture opportunities involving US national laboratories, research institutions and strategic partners and investors in
 
the US and Japan. His areas of expertise include corporate and securities law, broker-dealer regulation, venture capital, mergers and acquisitions, and the financing, development and commercial exploitation of technology and intellectual property in fields including computing and information technology, biotechnology and pharmaceuticals,
 
medical devices, media, entertainment and telecommunications. From 1988 to 2004, Simon was a partner and then of counsel with the New York law firm Snow Becker Krauss P. C. Simon graduated from Columbia College (Phi Beta Kappa, magna cum laude and John Jay Scholar) and Harvard Law School.

Nil Emre, PhD, is a Staff Scientist in the Stem Cell, Research and Development group at BD Biosciences in San Diego. She received her PhD in Biological Chemistry from UCLA in 2004 from the laboratory of Dr. Leonard Rome. From there she went on to pursue postdoctoral research at The Scripps Research Institute in the
 
laboratory of Dr. Sheng Ding where she focused on high throughput screening approaches to identify small molecules that regulate human embryonic stem cell differentiation. Dr. Emre joined Millipore Corporation in 2007 as a Research Scientist in Stem Cells/Cell Biology where she focused on stem
 
cell related product development, mainly centered on media development. In 2008, she joined the Stem Cell Research Group at BD Biosciences. The focus of the group is to develop antibody based research reagents and applications for stem cell research as well as to perform original scientific research.

Dr. Mridula specializes in Biotechnology and Ecotechnology assessment and intellectual property analysis. Dr. Mridula has 6 years of experience in patent and trademark portfolio management for startup to mid-size companies.
Dr. Mridula has unique experience with IP analysis, strategy and management in entrepreneurial environments. The technologies span a variety of scientific arenas including alternative fuels, natural pesticides, antimicrobial compounds, medical devices, gre enhouse gas reduction methods, cancer and diabetes therapeutics, cosmeceuticals and functional foods. She has served on numerous panels at IP and business development conferences speaking on intellectual property issues and concerns from a business development perspective.
 
Dr. Mridula brings this experience to her current role as Director and Partner of AccuDx, a business and technology development consulting company, where she is expanding their IP consulting services.
Dr. Mridula was the Intellectual Property Manager for XLTech Group, a business development company aimed at technology company spin-outs. In this role, her responsibilities included formulating the strategic plan of IP prosecution and portfolio expansion to meet business development goals within cost parameters, research and analysis of IP landscape for core and ancillary technologies under market and development evaluation, and presenting competitive IP landscape, Patentability, and freedom to operate evaluations to senior management team. In addition,
 
Dr. Mridula coordinated internal and external legal activit y related to Intellectual Property.
Dr. Mridula has also worked as a patent agent at the law firm of Baker Donelson Bearman Caldwell & Berkowitz, where she expanded her patent skills by assisting in draf ting patents, USPTO responses, communications to clients and foreign associates, patentability opinions and participating in client management in the life science sector.
Dr. Mridula completed her doctoral thesis in microbiology from the University of California, Los Angeles in 2004. Mridula became a registered US Patent Agent in April 2003 and an Investment Banking Representative (with ACN Securities, a boutique FINRA member investment firm) in August 2010.

Stephen is Executive Director of the Lee Count Economic Development Group, located in Keokuk, Iowa, an organization which attracts and assists industries which wish to expand to Lee County.Stephen previous served as an Iowa State Senator where he was
 
recognized by the American Legislative Exchange Council as their “Outstanding Legislator of the Year”. He has served in the Administration of President Ronald Reagan as Business/Government Relations Director, Mid-Atlantic Region,
 
for the U.S. Department of Commerce. In addition, Steve served as Executive Director of the American Chamber of Commerce in South Africa (AMCHAM). Steve is a graduate of Samford University